BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrug-resistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother. 2012;56:3271-3276. [PMID: 22391540 DOI: 10.1128/aac.06126-11] [Cited by in Crossref: 243] [Cited by in F6Publishing: 107] [Article Influence: 27.0] [Reference Citation Analysis]
Number Citing Articles
1 Leung CC, Porcel JM, Takahashi K, Restrepo MI, Lee P, Wainwright C. Year in review 2013: Lung cancer, respiratory infections, tuberculosis, cystic fibrosis, pleural diseases, bronchoscopic intervention and imaging. Respirology 2014;19:448-60. [PMID: 24708034 DOI: 10.1111/resp.12250] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
2 Goel D. Bedaquiline: A novel drug to combat multiple drug-resistant tuberculosis. J Pharmacol Pharmacother 2014;5:76-8. [PMID: 24554919 DOI: 10.4103/0976-500X.124435] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
3 Lanoix JP, Betoudji F, Nuermberger E. Novel regimens identified in mice for treatment of latent tuberculosis infection in contacts of patients with multidrug-resistant tuberculosis. Antimicrob Agents Chemother 2014;58:2316-21. [PMID: 24492372 DOI: 10.1128/AAC.02658-13] [Cited by in Crossref: 23] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]
4 Bastos ML, Hussain H, Weyer K, Garcia-Garcia L, Leimane V, Leung CC, Narita M, Penã JM, Ponce-de-Leon A, Seung KJ, Shean K, Sifuentes-Osornio J, Van der Walt M, Van der Werf TS, Yew WW, Menzies D; Collaborative Group for Meta-analysis of Individual Patient Data in MDR-TB. Treatment outcomes of patients with multidrug-resistant and extensively drug-resistant tuberculosis according to drug susceptibility testing to first- and second-line drugs: an individual patient data meta-analysis. Clin Infect Dis 2014;59:1364-74. [PMID: 25097082 DOI: 10.1093/cid/ciu619] [Cited by in Crossref: 88] [Cited by in F6Publishing: 86] [Article Influence: 12.6] [Reference Citation Analysis]
5 Singh B, Cocker D, Ryan H, Sloan DJ. Linezolid for drug-resistant pulmonary tuberculosis. Cochrane Database Syst Rev 2019;3:CD012836. [PMID: 30893466 DOI: 10.1002/14651858.CD012836.pub2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
6 Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 2013;57:2199-203. [PMID: 23459487 DOI: 10.1128/AAC.02243-12] [Cited by in Crossref: 49] [Cited by in F6Publishing: 21] [Article Influence: 6.1] [Reference Citation Analysis]
7 Kaniga K, Cirillo DM, Hoffner S, Ismail NA, Kaur D, Lounis N, Metchock B, Pfyffer GE, Venter A. A Multilaboratory, Multicountry Study To Determine Bedaquiline MIC Quality Control Ranges for Phenotypic Drug Susceptibility Testing. J Clin Microbiol 2016;54:2956-62. [PMID: 27654337 DOI: 10.1128/JCM.01123-16] [Cited by in Crossref: 24] [Cited by in F6Publishing: 14] [Article Influence: 4.8] [Reference Citation Analysis]
8 Verdugo D, Fallows D, Ahuja S, Schluger N, Kreiswirth B, Mathema B. Epidemiologic Correlates of Pyrazinamide-Resistant Mycobacterium tuberculosis in New York City. Antimicrob Agents Chemother 2015;59:6140-50. [PMID: 26195530 DOI: 10.1128/AAC.00764-15] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
9 Campbell JR, Falzon D, Mirzayev F, Jaramillo E, Migliori GB, Mitnick CD, Ndjeka N, Menzies D. Improving Quality of Patient Data for Treatment of Multidrug- or Rifampin-Resistant Tuberculosis. Emerg Infect Dis 2020;26. [PMID: 31922953 DOI: 10.3201/eid2603.190997] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
10 D'Elia JA, Weinrauch LA. Calcium Ion Channels: Roles in Infection and Sepsis Mechanisms of Calcium Channel Blocker Benefits in Immunocompromised Patients at Risk for Infection. Int J Mol Sci. 2018;19. [PMID: 30134544 DOI: 10.3390/ijms19092465] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
11 Lakshmanan M, Xavier AS. Bedaquiline - The first ATP synthase inhibitor against multi drug resistant tuberculosis. J Young Pharm 2013;5:112-5. [PMID: 24563587 DOI: 10.1016/j.jyp.2013.12.002] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 5.3] [Reference Citation Analysis]
12 Hu M, Zheng C, Gao F. Use of bedaquiline and delamanid in diabetes patients: clinical and pharmacological considerations. Drug Des Devel Ther 2016;10:3983-94. [PMID: 27994440 DOI: 10.2147/DDDT.S121630] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
13 Khare G, Kumar P, Tyagi AK. Whole-cell screening-based identification of inhibitors against the intraphagosomal survival of Mycobacterium tuberculosis. Antimicrob Agents Chemother 2013;57:6372-7. [PMID: 24060878 DOI: 10.1128/AAC.01444-13] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
14 Li S, Han Z, He J, Gao S, Liu D, Liu L, He J, Huang Y, Xu S, Mao W, Tan Q, Chen C, Li X, Zhang Z, Jiang G, Xu L, Zhang L, Fu J, Li H, Wang Q, Tan L, Li D, Zhou Q, Fu X, Jiang Z, Chen H, Fang W, Zhang X, Li Y, Tong T, Yu Z, Liu Y, Zhi X, Yan T, Zhang X, Imperatori A, Ibrahim M, Novoa NM, Ng CSH, Petersen RH, Chen JS, Fukuchi Y, Brunelli A, Ismail M, Valverde JA, Rodriguez-Lucas C. Society for Translational Medicine expert consensus on the use of antibacterial drugs in thoracic surgery. J Thorac Dis 2018;10:6356-74. [PMID: 30622808 DOI: 10.21037/jtd.2018.10.108] [Reference Citation Analysis]
15 Shi L, Gao J, Gao M, Deng P, Chen S, He M, Feng W, Yang X, Huang Y, He F, Hu Y, Lei L, Li X, Du J, Hu X, Liu Z, Tang P, Han J, Wang H, Han Y, Shu W, Sun Y, Pei Y, Liu Y. Interim Effectiveness and Safety Comparison of Bedaquiline-Containing Regimens for Treatment of Diabetic Versus Non-Diabetic MDR/XDR-TB Patients in China: A Multicenter Retrospective Cohort Study. Infect Dis Ther 2021;10:457-70. [PMID: 33515206 DOI: 10.1007/s40121-021-00396-9] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Ngo LT, Okogun JI, Folk WR. 21st century natural product research and drug development and traditional medicines. Nat Prod Rep 2013;30:584-92. [PMID: 23450245 DOI: 10.1039/c3np20120a] [Cited by in Crossref: 119] [Cited by in F6Publishing: 89] [Article Influence: 14.9] [Reference Citation Analysis]
17 Barbaro L, Nagalingam G, Triccas JA, Tan L, West NP, Baell JB, Priebbenow DL. Synthesis and evaluation of pyridine-derived bedaquiline analogues containing modifications at the A-ring subunit. RSC Med Chem 2021;12:943-59. [PMID: 34223160 DOI: 10.1039/d1md00063b] [Reference Citation Analysis]
18 Woodman M, Haeusler IL, Grandjean L. Tuberculosis Genetic Epidemiology: A Latin American Perspective. Genes (Basel) 2019;10:E53. [PMID: 30654542 DOI: 10.3390/genes10010053] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
19 Shanley CA, Ireton GC, Baldwin SL, Coler RN, Reed SG, Basaraba RJ, Orme IM. Therapeutic vaccination against relevant high virulence clinical isolates of Mycobacterium tuberculosis. Tuberculosis (Edinb) 2014;94:140-7. [PMID: 24295653 DOI: 10.1016/j.tube.2013.08.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
20 Fox GJ, Menzies D. A Review of the Evidence for Using Bedaquiline (TMC207) to Treat Multi-Drug Resistant Tuberculosis. Infect Dis Ther. 2013;2:123-144. [PMID: 25134476 DOI: 10.1007/s40121-013-0009-3] [Cited by in Crossref: 71] [Cited by in F6Publishing: 65] [Article Influence: 8.9] [Reference Citation Analysis]
21 Alvin A, Miller KI, Neilan BA. Exploring the potential of endophytes from medicinal plants as sources of antimycobacterial compounds. Microbiol Res 2014;169:483-95. [PMID: 24582778 DOI: 10.1016/j.micres.2013.12.009] [Cited by in Crossref: 166] [Cited by in F6Publishing: 94] [Article Influence: 23.7] [Reference Citation Analysis]
22 Lunn AM, Unnikrishnan M, Perrier S. Dual pH-Responsive Macrophage-Targeted Isoniazid Glycoparticles for Intracellular Tuberculosis Therapy. Biomacromolecules 2021. [PMID: 34339606 DOI: 10.1021/acs.biomac.1c00554] [Reference Citation Analysis]
23 Yew WW, Koh WJ. Emerging strategies for the treatment of pulmonary tuberculosis: promise and limitations? Korean J Intern Med 2016;31:15-29. [PMID: 26767853 DOI: 10.3904/kjim.2016.31.1.15] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
24 Alexander DC, Vasireddy R, Vasireddy S, Philley JV, Brown-Elliott BA, Perry BJ, Griffith DE, Benwill JL, Cameron AD, Wallace RJ Jr. Emergence of mmpT5 Variants during Bedaquiline Treatment of Mycobacterium intracellulare Lung Disease. J Clin Microbiol 2017;55:574-84. [PMID: 27927925 DOI: 10.1128/JCM.02087-16] [Cited by in Crossref: 43] [Cited by in F6Publishing: 21] [Article Influence: 8.6] [Reference Citation Analysis]
25 Egbelowo O, Sarathy JP, Gausi K, Zimmerman MD, Wang H, Wijnant GJ, Kaya F, Gengenbacher M, Van N, Degefu Y, Nacy C, Aldridge BB, Carter CL, Denti P, Dartois V. Pharmacokinetics and Target Attainment of SQ109 in Plasma and Human-Like Tuberculosis Lesions in Rabbits. Antimicrob Agents Chemother 2021;65:e0002421. [PMID: 34228540 DOI: 10.1128/AAC.00024-21] [Reference Citation Analysis]
26 Bruhn DF, Scherman MS, Liu J, Scherbakov D, Meibohm B, Böttger EC, Lenaerts AJ, Lee RE. In vitro and in vivo Evaluation of Synergism between Anti-Tubercular Spectinamides and Non-Classical Tuberculosis Antibiotics. Sci Rep 2015;5:13985. [PMID: 26365087 DOI: 10.1038/srep13985] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.8] [Reference Citation Analysis]
27 Field SK. Bedaquiline for the treatment of multidrug-resistant tuberculosis: great promise or disappointment? Ther Adv Chronic Dis 2015;6:170-84. [PMID: 26137207 DOI: 10.1177/2040622315582325] [Cited by in Crossref: 52] [Cited by in F6Publishing: 44] [Article Influence: 8.7] [Reference Citation Analysis]
28 De Lorenzo S, Tiberi S. Tuberculosis a re-emerging disease. Intern Emerg Med 2012;7 Suppl 3:S185-7. [PMID: 23073855 DOI: 10.1007/s11739-012-0822-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
29 Cook GM, Hards K, Dunn E, Heikal A, Nakatani Y, Greening C, Crick DC, Fontes FL, Pethe K, Hasenoehrl E, Berney M. Oxidative Phosphorylation as a Target Space for Tuberculosis: Success, Caution, and Future Directions. Microbiol Spectr 2017;5. [PMID: 28597820 DOI: 10.1128/microbiolspec.TBTB2-0014-2016] [Cited by in Crossref: 49] [Cited by in F6Publishing: 25] [Article Influence: 12.3] [Reference Citation Analysis]
30 Zhang AT, Montgomery MG, Leslie AGW, Cook GM, Walker JE. The structure of the catalytic domain of the ATP synthase from Mycobacterium smegmatis is a target for developing antitubercular drugs. Proc Natl Acad Sci U S A 2019;116:4206-11. [PMID: 30683723 DOI: 10.1073/pnas.1817615116] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 11.0] [Reference Citation Analysis]
31 Leibert E, Danckers M, Rom WN. New drugs to treat multidrug-resistant tuberculosis: the case for bedaquiline. Ther Clin Risk Manag 2014;10:597-602. [PMID: 25114537 DOI: 10.2147/TCRM.S37743] [Cited by in Crossref: 18] [Cited by in F6Publishing: 7] [Article Influence: 2.6] [Reference Citation Analysis]
32 Li Y, Sun F, Zhang W. Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging. Drug Dev Res 2019;80:98-105. [PMID: 30548290 DOI: 10.1002/ddr.21498] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 10.3] [Reference Citation Analysis]
33 Ismail NA, Aono A, Borroni E, Cirillo DM, Desmaretz C, Hasan R, Mitarai S, Shakoor S, Torrea G, Kaniga K, Omar SV. A Multimethod, Multicountry Evaluation of Breakpoints for Bedaquiline Resistance Determination. Antimicrob Agents Chemother 2020;64:e00479-20. [PMID: 32660992 DOI: 10.1128/AAC.00479-20] [Reference Citation Analysis]
34 Wong EB, Cohen KA, Bishai WR. Rising to the challenge: new therapies for tuberculosis. Trends Microbiol 2013;21:493-501. [PMID: 23764389 DOI: 10.1016/j.tim.2013.05.002] [Cited by in Crossref: 57] [Cited by in F6Publishing: 52] [Article Influence: 7.1] [Reference Citation Analysis]
35 Koul A, Vranckx L, Dhar N, Göhlmann HW, Özdemir E, Neefs JM, Schulz M, Lu P, Mørtz E, McKinney JD, Andries K, Bald D. Delayed bactericidal response of Mycobacterium tuberculosis to bedaquiline involves remodelling of bacterial metabolism. Nat Commun 2014;5:3369. [PMID: 24569628 DOI: 10.1038/ncomms4369] [Cited by in Crossref: 145] [Cited by in F6Publishing: 126] [Article Influence: 20.7] [Reference Citation Analysis]
36 Hasenoehrl EJ, Wiggins TJ, Berney M. Bioenergetic Inhibitors: Antibiotic Efficacy and Mechanisms of Action in Mycobacterium tuberculosis. Front Cell Infect Microbiol 2020;10:611683. [PMID: 33505923 DOI: 10.3389/fcimb.2020.611683] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
37 Grosset J, Vernon A. A reader's guide to the bactericidal activity of pyrazinamide and clofazimine alone and in combinations with pretomanid and bedaquiline. Am J Respir Crit Care Med 2015;191:871-3. [PMID: 25876201 DOI: 10.1164/rccm.201502-0367ED] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
38 Schito M, Migliori GB, Fletcher HA, McNerney R, Centis R, D'Ambrosio L, Bates M, Kibiki G, Kapata N, Corrah T, Bomanji J, Vilaplana C, Johnson D, Mwaba P, Maeurer M, Zumla A. Perspectives on Advances in Tuberculosis Diagnostics, Drugs, and Vaccines. Clin Infect Dis 2015;61Suppl 3:S102-18. [PMID: 26409271 DOI: 10.1093/cid/civ609] [Cited by in Crossref: 39] [Cited by in F6Publishing: 32] [Article Influence: 7.8] [Reference Citation Analysis]
39 Lee BY, Clemens DL, Silva A, Dillon BJ, Masleša-Galić S, Nava S, Ho CM, Horwitz MA. Ultra-rapid near universal TB drug regimen identified via parabolic response surface platform cures mice of both conventional and high susceptibility. PLoS One 2018;13:e0207469. [PMID: 30427938 DOI: 10.1371/journal.pone.0207469] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
40 Sotgiu G, D'Ambrosio L, Centis R, Mura I, Castiglia P, Spanevello A, Migliori GB. The multidrug-resistant tuberculosis threat: old problems and new solutions. J Thorac Dis 2015;7:E354-60. [PMID: 26543630 DOI: 10.3978/j.issn.2072-1439.2015.09.21] [Cited by in F6Publishing: 5] [Reference Citation Analysis]
41 Günther G. Multidrug-resistant and extensively drug-resistant tuberculosis: a review of current concepts and future challenges. Clin Med (Lond) 2014;14:279-85. [PMID: 24889573 DOI: 10.7861/clinmedicine.14-3-279] [Cited by in Crossref: 70] [Cited by in F6Publishing: 60] [Article Influence: 10.0] [Reference Citation Analysis]
42 Charan J, Reljic T, Kumar A. Bedaquiline versus placebo for management of multiple drug-resistant tuberculosis: A systematic review. Indian J Pharmacol 2016;48:186-91. [PMID: 27127322 DOI: 10.4103/0253-7613.178839] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
43 Cox HS, Furin JJ, Mitnick CD, Daniels C, Cox V, Goemaere E. The need to accelerate access to new drugs for multidrug-resistant tuberculosis. Bull World Health Organ 2015;93:491-7. [PMID: 26170507 DOI: 10.2471/BLT.14.138925] [Cited by in Crossref: 11] [Cited by in F6Publishing: 2] [Article Influence: 1.8] [Reference Citation Analysis]
44 Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:574-6. [PMID: 24126586 DOI: 10.1128/AAC.01462-13] [Cited by in Crossref: 109] [Cited by in F6Publishing: 43] [Article Influence: 13.6] [Reference Citation Analysis]
45 Lee Y, Mootien S, Shoen C, Destefano M, Cirillo P, Asojo OA, Yeung KR, Ledizet M, Cynamon MH, Aristoff PA, Koski RA, Kaplan PA, Anthony KG. Inhibition of mycobacterial alanine racemase activity and growth by thiadiazolidinones. Biochem Pharmacol 2013;86:222-30. [PMID: 23680030 DOI: 10.1016/j.bcp.2013.05.004] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
46 Mase S, Chorba T, Parks S, Belanger A, Dworkin F, Seaworth B, Warkentin J, Barry P, Shah N. Bedaquiline for the Treatment of Multidrug-resistant Tuberculosis in the United States. Clin Infect Dis 2020;71:1010-6. [PMID: 31556947 DOI: 10.1093/cid/ciz914] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 11.0] [Reference Citation Analysis]
47 Bhat MA, Al-Omar MA, Naglah AM, Khan AA. Synthesis of Novel Sulfamethaoxazole 4-Thiazolidinone Hybrids and Their Biological Evaluation. Molecules 2020;25:E3570. [PMID: 32781534 DOI: 10.3390/molecules25163570] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
48 Wells WA, Boehme CC, Cobelens FG, Daniels C, Dowdy D, Gardiner E, Gheuens J, Kim P, Kimerling ME, Kreiswirth B, Lienhardt C, Mdluli K, Pai M, Perkins MD, Peter T, Zignol M, Zumla A, Schito M. Alignment of new tuberculosis drug regimens and drug susceptibility testing: a framework for action. Lancet Infect Dis 2013;13:449-58. [PMID: 23531393 DOI: 10.1016/S1473-3099(13)70025-2] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.9] [Reference Citation Analysis]
49 Bastard M, Sanchez-Padilla E, du Cros P, Khamraev AK, Parpieva N, Tillyashaykov M, Hayrapetyan A, Kimenye K, Khurkhumal S, Dlamini T, Perez SF, Telnov A, Hewison C, Varaine F, Bonnet M. Outcomes of HIV-infected versus HIV-non-infected patients treated for drug-resistance tuberculosis: Multicenter cohort study. PLoS One 2018;13:e0193491. [PMID: 29518098 DOI: 10.1371/journal.pone.0193491] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
50 Sloan DJ, Davies GR, Khoo SH. Recent advances in tuberculosis: New drugs and treatment regimens. Curr Respir Med Rev 2013;9:200-10. [PMID: 24683386 DOI: 10.2174/1573398x113099990017] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
51 Kuksa L, Riekstina V, Leimane V, Ozere I, Skenders G, Van den Bergh R, Kremer K, Acosta CD, Harries AD. Multi- and extensively drug-resistant tuberculosis in Latvia: trends, characteristics and treatment outcomes. Public Health Action 2014;4:S47-53. [PMID: 26393098 DOI: 10.5588/pha.14.0041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
52 Tong AST, Choi PJ, Blaser A, Sutherland HS, Tsang SKY, Guillemont J, Motte M, Cooper CB, Andries K, Van den Broeck W, Franzblau SG, Upton AM, Denny WA, Palmer BD, Conole D. 6-Cyano Analogues of Bedaquiline as Less Lipophilic and Potentially Safer Diarylquinolines for Tuberculosis. ACS Med Chem Lett 2017;8:1019-24. [PMID: 29057044 DOI: 10.1021/acsmedchemlett.7b00196] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 11.5] [Reference Citation Analysis]
53 Dooley KE, Nuermberger EL, Diacon AH. Pipeline of drugs for related diseases: tuberculosis. Curr Opin HIV AIDS. 2013;8:579-585. [PMID: 24100880 DOI: 10.1097/coh.0000000000000009] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
54 Petri J, Nakatani Y, Montgomery MG, Ferguson SA, Aragão D, Leslie AGW, Heikal A, Walker JE, Cook GM. Structure of F1-ATPase from the obligate anaerobe Fusobacterium nucleatum. Open Biol 2019;9:190066. [PMID: 31238823 DOI: 10.1098/rsob.190066] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
55 Sarathy JP, Ganapathy US, Zimmerman MD, Dartois V, Gengenbacher M, Dick T. TBAJ-876, a 3,5-Dialkoxypyridine Analogue of Bedaquiline, Is Active against Mycobacterium abscessus. Antimicrob Agents Chemother 2020;64:e02404-19. [PMID: 31964791 DOI: 10.1128/AAC.02404-19] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 11.0] [Reference Citation Analysis]
56 Chua AP, Hoo GS, Chee CB, Wang YT. First use of bedaquiline in a patient with XDR-TB in Singapore. BMJ Case Rep 2015;2015:bcr2015210961. [PMID: 26400590 DOI: 10.1136/bcr-2015-210961] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
57 Matteelli A, Roggi A, Carvalho AC. Extensively drug-resistant tuberculosis: epidemiology and management. Clin Epidemiol. 2014;6:111-118. [PMID: 24729727 DOI: 10.2147/clep.s35839] [Cited by in Crossref: 63] [Cited by in F6Publishing: 29] [Article Influence: 9.0] [Reference Citation Analysis]
58 Rakesh, Bruhn DF, Scherman MS, Woolhiser LK, Madhura DB, Maddox MM, Singh AP, Lee RB, Hurdle JG, McNeil MR, Lenaerts AJ, Meibohm B, Lee RE. Pentacyclic nitrofurans with in vivo efficacy and activity against nonreplicating Mycobacterium tuberculosis. PLoS One 2014;9:e87909. [PMID: 24505329 DOI: 10.1371/journal.pone.0087909] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
59 Gao W, Kim JY, Anderson JR, Akopian T, Hong S, Jin YY, Kandror O, Kim JW, Lee IA, Lee SY, McAlpine JB, Mulugeta S, Sunoqrot S, Wang Y, Yang SH, Yoon TM, Goldberg AL, Pauli GF, Suh JW, Franzblau SG, Cho S. The cyclic peptide ecumicin targeting ClpC1 is active against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2015;59:880-9. [PMID: 25421483 DOI: 10.1128/AAC.04054-14] [Cited by in Crossref: 92] [Cited by in F6Publishing: 42] [Article Influence: 13.1] [Reference Citation Analysis]
60 Nimbalkar UD, Seijas JA, Borkute R, Damale MG, Sangshetti JN, Sarkar D, Nikalje APG. Ultrasound Assisted Synthesis of 4-(Benzyloxy)-N-(3-chloro-2-(substitutedphenyl)-4-oxoazetidin-1-yl) Benzamide as Challenging Anti-Tubercular Scaffold. Molecules 2018;23:E1945. [PMID: 30081525 DOI: 10.3390/molecules23081945] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
61 Kaplan SR, Topal J, Sosa L, Malinis M, Huttner A, Malhotra A, Friedland G. A patient with central nervous system tuberculomas and a history of disseminated multi-drug-resistant tuberculosis. J Clin Tuberc Other Mycobact Dis 2018;10:9-16. [PMID: 31720380 DOI: 10.1016/j.jctube.2017.12.004] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
62 Pecora F, Dal Canto G, Veronese P, Esposito S. Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid. Microorganisms 2021;9:1074. [PMID: 34067732 DOI: 10.3390/microorganisms9051074] [Reference Citation Analysis]
63 Mirsaeidi M. After 40 years, new medicine for combating TB. Int J Mycobacteriol 2013;2:1-2. [PMID: 25045621 DOI: 10.1016/j.ijmyco.2013.01.004] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
64 Pethe K, Bifani P, Jang J, Kang S, Park S, Ahn S, Jiricek J, Jung J, Jeon HK, Cechetto J, Christophe T, Lee H, Kempf M, Jackson M, Lenaerts AJ, Pham H, Jones V, Seo MJ, Kim YM, Seo M, Seo JJ, Park D, Ko Y, Choi I, Kim R, Kim SY, Lim S, Yim SA, Nam J, Kang H, Kwon H, Oh CT, Cho Y, Jang Y, Kim J, Chua A, Tan BH, Nanjundappa MB, Rao SP, Barnes WS, Wintjens R, Walker JR, Alonso S, Lee S, Kim J, Oh S, Oh T, Nehrbass U, Han SJ, No Z, Lee J, Brodin P, Cho SN, Nam K, Kim J. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis. Nat Med 2013;19:1157-60. [PMID: 23913123 DOI: 10.1038/nm.3262] [Cited by in Crossref: 352] [Cited by in F6Publishing: 310] [Article Influence: 44.0] [Reference Citation Analysis]
65 Li L, Li Z, Liu M, Shen W, Wang B, Guo H, Lu Y. Design, Synthesis and Antimycobacterial Activity of Novel Imidazo[1,2-a]pyridine Amide-Cinnamamide Hybrids. Molecules 2015;21:E49. [PMID: 26729085 DOI: 10.3390/molecules21010049] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
66 Upton AM, Cho S, Yang TJ, Kim Y, Wang Y, Lu Y, Wang B, Xu J, Mdluli K, Ma Z, Franzblau SG. In vitro and in vivo activities of the nitroimidazole TBA-354 against Mycobacterium tuberculosis. Antimicrob Agents Chemother 2015;59:136-44. [PMID: 25331696 DOI: 10.1128/AAC.03823-14] [Cited by in Crossref: 57] [Cited by in F6Publishing: 25] [Article Influence: 8.1] [Reference Citation Analysis]
67 Kaushik A, Ammerman NC, Tyagi S, Saini V, Vervoort I, Lachau-Durand S, Nuermberger E, Andries K. Activity of a Long-Acting Injectable Bedaquiline Formulation in a Paucibacillary Mouse Model of Latent Tuberculosis Infection. Antimicrob Agents Chemother 2019;63:e00007-19. [PMID: 30745396 DOI: 10.1128/AAC.00007-19] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 6.0] [Reference Citation Analysis]
68 Wang H, Zhang X, Bai Y, Duan Z, Lin Y, Wang G, Li F. Comparative efficacy and acceptability of five anti-tubercular drugs in treatment of multidrug resistant tuberculosis: a network meta-analysis. J Clin Bioinforma 2015;5:5. [PMID: 25937888 DOI: 10.1186/s13336-015-0020-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
69 Janssen S, Jayachandran R, Khathi L, Zinsstag J, Grobusch MP, Pieters J. Exploring prospects of novel drugs for tuberculosis. Drug Des Devel Ther 2012;6:217-24. [PMID: 22973091 DOI: 10.2147/DDDT.S34006] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 0.2] [Reference Citation Analysis]
70 Sarathy JP, Ragunathan P, Shin J, Cooper CB, Upton AM, Grüber G, Dick T. TBAJ-876 Retains Bedaquiline's Activity against Subunits c and ε of Mycobacterium tuberculosis F-ATP Synthase. Antimicrob Agents Chemother 2019;63:e01191-19. [PMID: 31358589 DOI: 10.1128/AAC.01191-19] [Cited by in Crossref: 17] [Cited by in F6Publishing: 7] [Article Influence: 8.5] [Reference Citation Analysis]
71 Phillips PPJ, Mitnick CD, Neaton JD, Nahid P, Lienhardt C, Nunn AJ. Keeping phase III tuberculosis trials relevant: Adapting to a rapidly changing landscape. PLoS Med 2019;16:e1002767. [PMID: 30901331 DOI: 10.1371/journal.pmed.1002767] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 5.5] [Reference Citation Analysis]
72 Whitfield MG, Soeters HM, Warren RM, York T, Sampson SL, Streicher EM, van Helden PD, van Rie A. A Global Perspective on Pyrazinamide Resistance: Systematic Review and Meta-Analysis. PLoS One 2015;10:e0133869. [PMID: 26218737 DOI: 10.1371/journal.pone.0133869] [Cited by in Crossref: 71] [Cited by in F6Publishing: 63] [Article Influence: 11.8] [Reference Citation Analysis]
73 Grace AG, Mittal A, Jain S, Tripathy JP, Satyanarayana S, Tharyan P, Kirubakaran R. Shortened treatment regimens versus the standard regimen for drug-sensitive pulmonary tuberculosis. Cochrane Database Syst Rev 2019;12:CD012918. [PMID: 31828771 DOI: 10.1002/14651858.CD012918.pub2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
74 Sarathy JP, Gruber G, Dick T. Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline. Antibiotics (Basel) 2019;8:E261. [PMID: 31835707 DOI: 10.3390/antibiotics8040261] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 6.0] [Reference Citation Analysis]
75 D'Ambrosio L, Centis R, Sotgiu G, Pontali E, Spanevello A, Migliori GB. New anti-tuberculosis drugs and regimens: 2015 update. ERJ Open Res 2015;1:00010-2015. [PMID: 27730131 DOI: 10.1183/23120541.00010-2015] [Cited by in Crossref: 45] [Cited by in F6Publishing: 40] [Article Influence: 7.5] [Reference Citation Analysis]
76 Gualano G, Capone S, Matteelli A, Palmieri F. New Antituberculosis Drugs: From Clinical Trial to Programmatic Use. Infect Dis Rep 2016;8:6569. [PMID: 27403268 DOI: 10.4081/idr.2016.6569] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 7.2] [Reference Citation Analysis]
77 Peraman R, Sure SK, Dusthackeer VNA, Chilamakuru NB, Yiragamreddy PR, Pokuri C, Kutagulla VK, Chinni S. Insights on recent approaches in drug discovery strategies and untapped drug targets against drug resistance. Futur J Pharm Sci 2021;7:56. [PMID: 33686369 DOI: 10.1186/s43094-021-00196-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
78 Svensson EM, Murray S, Karlsson MO, Dooley KE. Rifampicin and rifapentine significantly reduce concentrations of bedaquiline, a new anti-TB drug. J Antimicrob Chemother 2015;70:1106-14. [PMID: 25535219 DOI: 10.1093/jac/dku504] [Cited by in Crossref: 20] [Cited by in F6Publishing: 33] [Article Influence: 2.9] [Reference Citation Analysis]
79 Momin MAM, Rangnekar B, Sinha S, Cheung CY, Cook GM, Das SC. Inhalable Dry Powder of Bedaquiline for Pulmonary Tuberculosis: In Vitro Physicochemical Characterization, Antimicrobial Activity and Safety Studies. Pharmaceutics 2019;11:E502. [PMID: 31581469 DOI: 10.3390/pharmaceutics11100502] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
80 Giraud-Gatineau A, Coya JM, Maure A, Biton A, Thomson M, Bernard EM, Marrec J, Gutierrez MG, Larrouy-Maumus G, Brosch R, Gicquel B, Tailleux L. The antibiotic bedaquiline activates host macrophage innate immune resistance to bacterial infection. Elife 2020;9:e55692. [PMID: 32369020 DOI: 10.7554/eLife.55692] [Cited by in Crossref: 19] [Cited by in F6Publishing: 11] [Article Influence: 19.0] [Reference Citation Analysis]
81 Hartkoorn RC, Uplekar S, Cole ST. Cross-resistance between clofazimine and bedaquiline through upregulation of MmpL5 in Mycobacterium tuberculosis. Antimicrob Agents Chemother 2014;58:2979-81. [PMID: 24590481 DOI: 10.1128/AAC.00037-14] [Cited by in Crossref: 254] [Cited by in F6Publishing: 114] [Article Influence: 36.3] [Reference Citation Analysis]
82 Zhao Y, Fox T, Manning K, Stewart A, Tiffin N, Khomo N, Leslie J, Boulle A, Mudaly V, Kock Y, Meintjes G, Wasserman S. Improved Treatment Outcomes With Bedaquiline When Substituted for Second-line Injectable Agents in Multidrug-resistant Tuberculosis: A Retrospective Cohort Study. Clin Infect Dis 2019;68:1522-9. [PMID: 30165431 DOI: 10.1093/cid/ciy727] [Cited by in Crossref: 14] [Cited by in F6Publishing: 17] [Article Influence: 14.0] [Reference Citation Analysis]
83 Undela K. Sirturo (Bedaquiline): The first new anti tubercular drug in decades. World J Meta-Anal 2013; 1(1): 8-9 [DOI: 10.13105/wjma.v1.i1.8] [Reference Citation Analysis]
84 Sotgiu G, Centis R, D'ambrosio L, Migliori GB. Tuberculosis treatment and drug regimens. Cold Spring Harb Perspect Med 2015;5:a017822. [PMID: 25573773 DOI: 10.1101/cshperspect.a017822] [Cited by in Crossref: 71] [Cited by in F6Publishing: 55] [Article Influence: 11.8] [Reference Citation Analysis]
85 Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 2014;9:e102135. [PMID: 25010492 DOI: 10.1371/journal.pone.0102135] [Cited by in Crossref: 203] [Cited by in F6Publishing: 173] [Article Influence: 29.0] [Reference Citation Analysis]
86 Irwin SM, Prideaux B, Lyon ER, Zimmerman MD, Brooks EJ, Schrupp CA, Chen C, Reichlen MJ, Asay BC, Voskuil MI, Nuermberger EL, Andries K, Lyons MA, Dartois V, Lenaerts AJ. Bedaquiline and Pyrazinamide Treatment Responses Are Affected by Pulmonary Lesion Heterogeneity in Mycobacterium tuberculosis Infected C3HeB/FeJ Mice. ACS Infect Dis 2016;2:251-67. [PMID: 27227164 DOI: 10.1021/acsinfecdis.5b00127] [Cited by in Crossref: 63] [Cited by in F6Publishing: 59] [Article Influence: 12.6] [Reference Citation Analysis]
87 Choi PJ, Sutherland HS, Tong AST, Blaser A, Franzblau SG, Cooper CB, Lotlikar MU, Upton AM, Guillemont J, Motte M, Queguiner L, Andries K, Van den Broeck W, Denny WA, Palmer BD. Synthesis and evaluation of analogues of the tuberculosis drug bedaquiline containing heterocyclic B-ring units. Bioorg Med Chem Lett 2017;27:5190-6. [PMID: 29107541 DOI: 10.1016/j.bmcl.2017.10.042] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 9.0] [Reference Citation Analysis]
88 Svensson EM, Dosne AG, Karlsson MO. Population Pharmacokinetics of Bedaquiline and Metabolite M2 in Patients With Drug-Resistant Tuberculosis: The Effect of Time-Varying Weight and Albumin. CPT Pharmacometrics Syst Pharmacol 2016;5:682-91. [PMID: 27863179 DOI: 10.1002/psp4.12147] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.8] [Reference Citation Analysis]
89 Dookie N, Sturm AW, Moodley P. Mechanisms of first-line antimicrobial resistance in multi-drug and extensively drug resistant strains of Mycobacterium tuberculosis in KwaZulu-Natal, South Africa. BMC Infect Dis 2016;16:609. [PMID: 27784282 DOI: 10.1186/s12879-016-1906-3] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
90 Doan TN, Cao P, Emeto TI, McCaw JM, McBryde ES. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling. Antimicrob Agents Chemother 2018;62:e01487-18. [PMID: 30249697 DOI: 10.1128/AAC.01487-18] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
91 Outhred AC, Jelfs P, Suliman B, Hill-Cawthorne GA, Crawford AB, Marais BJ, Sintchenko V. Added value of whole-genome sequencing for management of highly drug-resistant TB. J Antimicrob Chemother 2015;70:1198-202. [PMID: 25492392 DOI: 10.1093/jac/dku508] [Cited by in Crossref: 9] [Cited by in F6Publishing: 17] [Article Influence: 1.3] [Reference Citation Analysis]
92 Ordonez AA, Carroll LS, Abhishek S, Mota F, Ruiz-Bedoya CA, Klunk MH, Singh AK, Freundlich JS, Mease RC, Jain SK. Radiosynthesis and PET Bioimaging of 76Br-Bedaquiline in a Murine Model of Tuberculosis. ACS Infect Dis 2019;5:1996-2002. [PMID: 31345032 DOI: 10.1021/acsinfecdis.9b00207] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 5.0] [Reference Citation Analysis]
93 Wang Y, Siricilla S, Aleiwi BA, Kurosu M. Improved synthesis of capuramycin and its analogues. Chemistry 2013;19:13847-58. [PMID: 24014478 DOI: 10.1002/chem.201302389] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
94 Liu K, Li F, Lu J, Liu S, Dorko K, Xie W, Ma X. Bedaquiline metabolism: enzymes and novel metabolites. Drug Metab Dispos 2014;42:863-6. [PMID: 24513655 DOI: 10.1124/dmd.113.056119] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
95 Gaida R, Truter I, Peters CA. Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis. S Afr J Infect Dis 2020;35:23. [PMID: 34485463 DOI: 10.4102/sajid.v35i1.23] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
96 Hu X, Wan B, Liu Y, Shen J, Franzblau SG, Zhang T, Ding K, Lu X. Identification of Pyrazolo[1,5-a]pyridine-3-carboxamide Diaryl Derivatives as Drug Resistant Antituberculosis Agents. ACS Med Chem Lett 2019;10:295-9. [PMID: 30891129 DOI: 10.1021/acsmedchemlett.8b00410] [Cited by in Crossref: 8] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
97 Ziganshina LE, Titarenko AF, Davies GR. Fluoroquinolones for treating tuberculosis (presumed drug-sensitive). Cochrane Database Syst Rev 2013;:CD004795. [PMID: 23744519 DOI: 10.1002/14651858.CD004795.pub4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
98 Ahmad I, Jadhav H, Shinde Y, Jagtap V, Girase R, Patel H. Optimizing Bedaquiline for cardiotoxicity by structure based virtual screening, DFT analysis and molecular dynamic simulation studies to identify selective MDR-TB inhibitors. In Silico Pharmacol 2021;9:23. [PMID: 33854869 DOI: 10.1007/s40203-021-00086-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
99 Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO. Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis. Antimicrob Agents Chemother 2013;57:2780-7. [PMID: 23571542 DOI: 10.1128/AAC.00191-13] [Cited by in Crossref: 58] [Cited by in F6Publishing: 28] [Article Influence: 7.3] [Reference Citation Analysis]
100 Gupta S, Tyagi S, Bishai WR. Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model. Antimicrob Agents Chemother 2015;59:673-6. [PMID: 25331694 DOI: 10.1128/AAC.04019-14] [Cited by in Crossref: 42] [Cited by in F6Publishing: 19] [Article Influence: 6.0] [Reference Citation Analysis]
101 Sutherland HS, Tong AST, Choi PJ, Conole D, Blaser A, Franzblau SG, Cooper CB, Upton AM, Lotlikar MU, Denny WA, Palmer BD. Structure-activity relationships for analogs of the tuberculosis drug bedaquiline with the naphthalene unit replaced by bicyclic heterocycles. Bioorg Med Chem 2018;26:1797-809. [PMID: 29482950 DOI: 10.1016/j.bmc.2018.02.026] [Cited by in Crossref: 46] [Cited by in F6Publishing: 35] [Article Influence: 15.3] [Reference Citation Analysis]
102 Svensson EM, Karlsson MO. Modelling of mycobacterial load reveals bedaquiline's exposure-response relationship in patients with drug-resistant TB. J Antimicrob Chemother 2017;72:3398-405. [PMID: 28961790 DOI: 10.1093/jac/dkx317] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 7.3] [Reference Citation Analysis]
103 Cohen KA, Manson AL, Desjardins CA, Abeel T, Earl AM. Deciphering drug resistance in Mycobacterium tuberculosis using whole-genome sequencing: progress, promise, and challenges. Genome Med 2019;11:45. [PMID: 31345251 DOI: 10.1186/s13073-019-0660-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 14.0] [Reference Citation Analysis]
104 Svensson EM, Dooley KE, Karlsson MO. Impact of lopinavir-ritonavir or nevirapine on bedaquiline exposures and potential implications for patients with tuberculosis-HIV coinfection. Antimicrob Agents Chemother 2014;58:6406-12. [PMID: 25114140 DOI: 10.1128/AAC.03246-14] [Cited by in Crossref: 40] [Cited by in F6Publishing: 18] [Article Influence: 5.7] [Reference Citation Analysis]
105 Blaser A, Sutherland HS, Tong AST, Choi PJ, Conole D, Franzblau SG, Cooper CB, Upton AM, Lotlikar M, Denny WA, Palmer BD. Structure-activity relationships for unit C pyridyl analogues of the tuberculosis drug bedaquiline. Bioorg Med Chem 2019;27:1283-91. [PMID: 30792104 DOI: 10.1016/j.bmc.2019.02.025] [Cited by in Crossref: 28] [Cited by in F6Publishing: 23] [Article Influence: 14.0] [Reference Citation Analysis]
106 Tanner L, Mashabela GT, Omollo CC, de Wet TJ, Parkinson CJ, Warner DF, Haynes RK, Wiesner L. Intracellular Accumulation of Novel and Clinically Used TB Drugs Potentiates Intracellular Synergy. Microbiol Spectr 2021;9:e0043421. [PMID: 34585951 DOI: 10.1128/Spectrum.00434-21] [Reference Citation Analysis]
107 Whitfield MG, Marras SAE, Warren RM, Van Rie A, Rice J, Wangh LJ, Kreiswirth BN. Rapid Pyrazinamide Drug Susceptibility Testing using a Closed-Tube PCR Assay of the Entire pncA gene. Sci Rep 2020;10:4234. [PMID: 32144379 DOI: 10.1038/s41598-020-61286-7] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]